Case Report: A case of reversible pulmonary bullae induced by camrelizumab: a new immune-related adverse event
With the widespread clinical application of immune checkpoint inhibitors (ICIs), the treatment of lung squamous cell carcinoma (LUSC) has entered a new era, characterized by equal emphasis on precision medicine and immunotherapy. Among these, programme…